Harmony Biosciences Holdings earnings release, August 4, 2026

Harmony Biosciences Holdings, Inc. (HRMY) · Form 8-K, Item 2.02 · Filed · SEC filing

‌

Harmony Biosciences Announces Record Q2 2026 Re venue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

WAKIX® Net Revenue Grew 30% Year over Year to

$261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950;

Reiterates

2026

WAKIX

Net Revenue Guidance of $1.

0 Billion to $1.04 Billion

Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Safety/Tolerability Profiles; Phase 1 MAD Data Expected in Q4 2026

BP-205 IND Open in US; Initiating Phase 1b Study in Sleep-Deprived Healthy Volunteers in Q3; Data Expected Early 2027

Initiating Phase 2 Trials for BP-205 in Mid-2027 to Evaluate Multiple CNS Indications

Pitolisant GR NDA Accepted in July; Target PDUFA Date April 1, 2027

Pitolisant HD On Track for Phase 3 Topline Data in 2027 and Target PDUFA Date in 2028

Conference Call and Webcast Today at 8:30 a.m. ET

​

PLYMOUTH MEETING, Pa., August 4, 2026 /Business Wire/

-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q2 2026 net revenue for WAKIX® (pitolisant) of $261.3 million, delivering 30% year-over-year growth in its seventh year on the market. These results underscore continued strong demand for WAKIX, disciplined commercial execution across the franchise and sustained momentum through the first half of 2026. Average patients for the quarter were approximately 8,950, an increase in average patients of 450. WAKIX remains on track to achieve full-year net revenue guidance of $1.0 billion to $1.04 billion.

​

​

The Company also announced encouraging single ascending dose (SAD) data from its Phase 1 study of BP-205, demonstrating favorable pharmacokinetic (PK) and safety/tolerability profiles that reinforce Harmony’s conviction in BP-205 as a potential best-in-class orexin-2 receptor (OX2R) agonist. These data support Harmony’s robust orexin development strategy, including initiating Phase 2 studies beginning in mid-2027 to evaluate multiple CNS indications.

​

“Our record second-quarter revenue reflects sustained demand for WAKIX and keeps us firmly on track to deliver over $1 billion in revenue this year. With this strong foundation, we are aggressively advancing our pipeline, with our orexin-2 agonist BP-205 as the centerpiece, that we believe can create significant long-term value for both patients and shareholders,” said Jeffrey M. Dayno, MD, President and Chief Executive Officer of Harmony Biosciences. “The Phase 1 clinical PK and safety/tolerability data for BP-205 that we shared today, together with pre-clinical data demonstrating the highest potency of any orexin-2 agonist currently in the clinic, reinforce our conviction that BP-205 has the potential to be the best-in-class orexin-2 agonist with broad clinical utility across multiple CNS indications.”

​

Bruce C. Corser, MD, Medical Director of the Sleep Management Institute, said, “The Phase 1 single ascending dose pharmacokinetic and safety/tolerability data for BP-205 are compelling. The potential for rapid onset of action and once-daily dosing, along with a favorable safety/tolerability profile, exceptional potency and high selectivity, suggests that BP-205 may have potential clinical utility in indications beyond orexin deficiency. I look forward to following the continued clinical development of this program.”

​

Key Drivers of Value Creation

​

Continued WAKIX Growth in an Evolving Market

​

Second Quarter 2026 Net Product Revenue for WAKIX

​

On Track to Achieve 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion

​

Advance a Robust, Self-Funded Pipeline

​

Orexin-2 receptor agonist BP-205 (BP1.15205) is Harmony’s OX2R agonist discovered by Teijin Pharma and developed in partnership with Bioprojet. It is designed to deliver a differentiated

​

​ profile through its high potency, excellent selectivity, favorable safety/tolerability, and a predictable PK profile with the potential for once-a-day dosing. It is the most potent OX2R agonist currently in clinical development.

​

​

​

​

Pitolisant GR (Gastro-resistant) Tablets: On track to launch in 1H 2027

​

Pitolisant HD (high dose): Opportunity to extend the pitolisant franchise with differentiated labeling

​

​

​

WAKIX (pitolisant): Phase 3 trial in PWS (TEMPO)

​

Exploring amorphous form of pitolisant to pursue broader CNS indications

​

EPX-100 (clemizole hydrochloride)

​

Emphasis on Business Development

​

​

Protect the Pitolisant Franchise

​

​

​

​

Second Quarter 2026 Financial Results

​

Harmony Biosciences reported net product revenue of $261.3 million for the quarter ended June 30, 2026, compared to $200.5 million for the same period in 2025, representing 30% year-over-year growth. This performance reflects continued strong demand for WAKIX within the large narcolepsy market opportunity (approximately 80,000 diagnosed patients in the U.S.), disciplined commercial execution across the franchise and the product's broad clinical utility. The continued success of WAKIX has been driven by strong demand and commercial execution.

Based on our results for the first half of 2026, WAKIX remains on track to achieve full-year net revenue of

$1.0 billion to

$1.04 billion.

​

Cost of product sold was $63.2 million in the second quarter of 2026, or 24.2% as a percentage of net product revenue, as compared to $38.2 million, or 19.0%, for the same quarter in 2025, representing a 66% increase. The increase in cost of product sold as a percentage of net product revenue was primarily driven by new royalties related to the Novitium license agreement.

​

Net income for the second quarter was $75.4 million, or $1.28 per diluted share, compared to $39.8 million, or $0.68 per diluted share, for the same quarter in 2025.

​

Harmony’s operating expenses include the following:

​

​

​

As of June 30, 2026, Harmony had cash, cash equivalents and investments of $962.5 million, compared to $882.5 million as of December 31, 2025.

​.26 Net Product Revenue Guidance

Reiterated 2026 WAKIX net revenue guidance of

$1.0 billion to

$1.04 billion.

​

Conference Call Today at 8:30 a.m. ET

Harmony is hosting its second quarter 2026 financial results conference call and webcast today, beginning at 8:30 a.m. Eastern Time. The live and replay webcast of the call will be available on the investor relations page of our website https://ir.harmonybiosciences.com/.

​

To participate in the live call by phone, dial: 800-347-6865

(primary) or

203-518-9757

(alternate); conference ID is HRMYQ226.

​

About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

​

Financial statements

Income Statement

Three Months Ended June 30, — (In thousands, except share and per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net product revenue261,280200,489476,667385,222
Cost of product sold63,19838,153107,71070,147
Gross profit198,082162,336368,957315,075
Operating expenses:Research and development46,59650,159115,97984,699
Operating expenses:Sales and marketing34,12030,07365,81460,784
Operating expenses:General and administrative28,05033,92460,55765,167
Operating expenses:Total operating expenses108,766114,156242,350210,650
Operating expenses:Operating income89,31648,180126,607104,425
Operating expenses:Other expense, net-53-193-180-469
Operating expenses:Interest expense-3,070-3,646-6,304-7,482
Operating expenses:Interest income7,0725,29612,82910,340
Operating expenses:Income before income taxes93,26549,637132,952106,814
Operating expenses:Income tax expense-17,834-9,861-25,033-21,478
Operating expenses:Net income75,43139,776107,91985,336
Operating expenses:Unrealized (loss) income on investments-314-6-1,073173
Operating expenses:Comprehensive income75,11739,770106,84685,509
EARNINGS PER SHARE:Basic1.30.691.861.49
EARNINGS PER SHARE:Diluted1.280.681.841.46
EARNINGS PER SHARE:Weighted average number of shares of common stock - basic57,933,81857,469,77557,876,75657,390,298
EARNINGS PER SHARE:Weighted average number of shares of common stock - diluted58,755,35958,427,13458,769,50458,468,717

Balance Sheet

December 31, — (In thousands, except share and per share data)

June 30, – 2026December 31, – 2025
CURRENT ASSETS:Cash and cash equivalents549,769752,502
CURRENT ASSETS:Investments, short-term118,02222,838
CURRENT ASSETS:Trade receivables, net110,99596,787
CURRENT ASSETS:Inventory, net6,3605,357
CURRENT ASSETS:Prepaid expenses19,31116,014
CURRENT ASSETS:Other current assets9,87713,516
CURRENT ASSETS:Total current assets814,334907,014
NONCURRENT ASSETS:Investments, long-term294,668107,127
NONCURRENT ASSETS:Intangible assets, net77,49689,418
NONCURRENT ASSETS:Deferred tax asset156,765149,699
NONCURRENT ASSETS:Other noncurrent assets29,82118,373
NONCURRENT ASSETS:Total noncurrent assets558,750364,617
NONCURRENT ASSETS:TOTAL ASSETS1,373,0841,271,631
CURRENT LIABILITIES:Trade payables21,68417,693
CURRENT LIABILITIES:Accrued compensation12,09118,443
CURRENT LIABILITIES:Accrued expenses169,128191,039
CURRENT LIABILITIES:Current portion of long-term debt20,00020,000
CURRENT LIABILITIES:Other current liabilities11,1674,957
CURRENT LIABILITIES:Total current liabilities234,070252,132
NONCURRENT LIABILITIES:Long-term debt, net133,961143,663
NONCURRENT LIABILITIES:Other noncurrent liabilities5,8105,618
NONCURRENT LIABILITIES:Total noncurrent liabilities139,771149,281
NONCURRENT LIABILITIES:TOTAL LIABILITIES373,841401,413
STOCKHOLDERS’ EQUITY:Common stock—$0.00001 par value; 500,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 58,120,695 and 57,726,170 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively11
STOCKHOLDERS’ EQUITY:Additional paid in capital731,147708,968
STOCKHOLDERS’ EQUITY:Accumulated other comprehensive (loss) income-727346
STOCKHOLDERS’ EQUITY:Retained earnings268,822160,903
STOCKHOLDERS’ EQUITY:TOTAL STOCKHOLDERS’ EQUITY999,243870,218
STOCKHOLDERS’ EQUITY:TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY1,373,0841,271,631
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2026 net product revenue, expectations for the growth and value of WAKIX, our planned and ongoing clinical trials and expected timing of data readouts, anticipated regulatory milestones, our future results of operations and financial position, business strategy, products, prospective products, product approvals, and the plans and objectives of management for future operations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX; the rate and degree of market acceptance and clinical utility of pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved, including EPX-100, Pitolisant GR and BP-205; our research and development plans, including our plans to explore the therapeutic potential of pitolisant in additional indications; our ongoing and planned clinical trials; our ability to expand the scope of our license agreements with Bioprojet Société Civile de Recherche (“Bioprojet”); the availability

​

​ of favorable insurance coverage and reimbursement for WAKIX; the timing of, and our ability to obtain, regulatory approvals for pitolisant for other indications as well as any other product candidates; our estimates regarding expenses, future revenue, capital requirements and additional financing needs; our ability to identify, acquire and integrate additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and manufacturing capabilities and strategy; significant competition in our industry; our intellectual property position; loss or retirement of key members of management; failure to successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the impact of government laws and regulations; volatility and fluctuations in the price of our common stock; the significant costs and required management time as a result of operating as a public company; the fact that the price of Harmony's common stock may be volatile and fluctuate substantially; statements related to our intended share repurchases and repurchase timeframe; and macroeconomic effects and changes in market conditions, including the impact of tariffs, inflation and the risk of recession. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 24, 2026 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

HARMONY BIOSCIENCES HOLDINGS,

INC.

AND SUBSIDIARIES

​

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Harmony Biosciences Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.